Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Not Applicable
1 (100.0%)Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
Completed
- Conditions
- Ocular Surface DiseasePrimary Open Angle Glaucoma
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Santen Pharmaceutical (Taiwan) Co., LTD
- Target Recruit Count
- 50
- Registration Number
- NCT04828057
- Locations
- 🇨🇳
Chang-Geng Medical Foundation Linkou Chang-Geng Memorial Hospital, Taoyuan city, Taiwan
Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)
Not Applicable
Completed
- Conditions
- Glaucoma, Primary Open Angle
- Interventions
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Santen Pharmaceutical (Taiwan) Co., LTD
- Target Recruit Count
- 1
- Registration Number
- NCT04737928
- Locations
- 🇨🇳
Chi Mei Hospital Liouying Branch, Tainan, Taiwan
News
No news found